EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis

Kim A Papp iD, April W Armstrong, Tomokazu Koresawa, Kazunari Otake iD, Masayuki Hirata, Akiko Kano

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20863 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Kim A Papp und 5 weiteren Autor:innen. Beteiligte Einrichtung: Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada. Hauptthemen laut MEDLINE: Psoriasis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Meiji Pharma USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is an unmet need for oral psoriasis medications with improved efficacy and safety.

Objective

We evaluated the efficacy and safety of oral ME3183, a novel phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis.

Methods

This was a randomized, double‐blind, placebo‐controlled study with a 16‐week double‐blind treatment period. Patients were randomly assigned (1:1:1:1:1) to oral ME3183 5 mg twice daily (BID), 10 mg once daily (QD), 7.5 mg BID, 15 mg QD or placebo.

Results

In total, 132 patients were randomly assigned to ME3183 5 mg BID (26 patients), 10 mg QD (26 patients), 7.5 mg BID (26 patients), 15 mg QD (27 patients) and placebo (27 patients). The proportions of patients achieving ≥75% reduction in baseline Psoriasis Area and Severity Index scores at Week 16 (primary endpoint) were 58.3%, 32.0%, 61.5% and 52.0% in each ME3183 group, respectively, versus 14.8% in the placebo group (all p < 0.01 vs. placebo, except for the 10 mg QD group). The most common adverse events across the ME3183 groups were diarrhoea (16.0%–38.5%), nausea (7.7%–30.8%) and headache (7.7%–42.3%).

Conclusions

ME3183 should be further investigated as a safe and effective treatment alternative for moderate to severe plaque psoriasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisPhosphodiesterase 4 InhibitorsHumansMaleFemaleDouble-Blind MethodMiddle AgedAdultAdministration, OralSeverity of Illness IndexTreatment OutcomeAgedPhthalic AcidsQuinazolines

Stichwörter der Autor:innen

ME3183efficacyphosphodiesterase 4 inhibitorplaque psoriasisrandomized controlled studysafety

Substanzen

Phosphodiesterase 4 Inhibitorsmethyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoatePhthalic AcidsQuinazolines

Autor:innen und Institutionen

  • Alliance Clinical Trials and Probity Medical Research, Waterloo, Ontario, Canada.
  • Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Division of Dermatology, University of California, Los Angeles, Los Angeles, California, USA.
  • Research & Development, Meiji Pharma USA Inc., Teaneck, New Jersey, USA.

ORCID-Profile: Kim A Papp, Kazunari Otake

Förderung

  • Meiji Pharma USA

Zitieren

APA

Papp, K. A., Armstrong, A. W., Koresawa, T., Otake, K., Hirata, M., & Kano, A. (2025). Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20863

Vancouver

Papp KA, Armstrong AW, Koresawa T, Otake K, Hirata M, Kano A. Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20863

BibTeX
@article{Papp2025,
  author = {Papp, Kim A and Armstrong, April W and Koresawa, Tomokazu and Otake, Kazunari and Hirata, Masayuki and Kano, Akiko},
  title = {Efficacy and safety of ME3183 , an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20863}
}
Kostenlos starten →